JP2017505285A5 - - Google Patents

Download PDF

Info

Publication number
JP2017505285A5
JP2017505285A5 JP2016532631A JP2016532631A JP2017505285A5 JP 2017505285 A5 JP2017505285 A5 JP 2017505285A5 JP 2016532631 A JP2016532631 A JP 2016532631A JP 2016532631 A JP2016532631 A JP 2016532631A JP 2017505285 A5 JP2017505285 A5 JP 2017505285A5
Authority
JP
Japan
Prior art keywords
therapeutic agent
agent according
salt
compound
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2016532631A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017505285A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/065742 external-priority patent/WO2015077154A1/en
Publication of JP2017505285A publication Critical patent/JP2017505285A/ja
Publication of JP2017505285A5 publication Critical patent/JP2017505285A5/ja
Withdrawn legal-status Critical Current

Links

JP2016532631A 2013-11-20 2014-11-14 ホモ接合性家族性高コレステロール血症の治療 Withdrawn JP2017505285A (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201361906837P 2013-11-20 2013-11-20
US61/906,837 2013-11-20
US201461942438P 2014-02-20 2014-02-20
US61/942,438 2014-02-20
US201461942941P 2014-02-21 2014-02-21
US61/942,941 2014-02-21
US201461974725P 2014-04-03 2014-04-03
US201461974816P 2014-04-03 2014-04-03
US201461974785P 2014-04-03 2014-04-03
US61/974,816 2014-04-03
US61/974,725 2014-04-03
US61/974,785 2014-04-03
PCT/US2014/065742 WO2015077154A1 (en) 2013-11-20 2014-11-14 Treatment of homozygous familial hypercholesterolemia

Publications (2)

Publication Number Publication Date
JP2017505285A JP2017505285A (ja) 2017-02-16
JP2017505285A5 true JP2017505285A5 (https=) 2017-12-21

Family

ID=52014370

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016532631A Withdrawn JP2017505285A (ja) 2013-11-20 2014-11-14 ホモ接合性家族性高コレステロール血症の治療

Country Status (14)

Country Link
US (1) US20150139987A1 (https=)
EP (1) EP3071198A1 (https=)
JP (1) JP2017505285A (https=)
KR (1) KR20160079124A (https=)
CN (1) CN105764498A (https=)
AU (1) AU2014353246A1 (https=)
CA (1) CA2930069A1 (https=)
CL (1) CL2016001215A1 (https=)
EA (1) EA201691039A1 (https=)
HK (1) HK1224186A1 (https=)
IL (1) IL245748A0 (https=)
MX (1) MX2016006583A (https=)
PH (1) PH12016500886A1 (https=)
WO (1) WO2015077154A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
IL292159B1 (en) 2012-12-05 2026-04-01 Alnylam Pharmaceuticals Inc PCSK9 iRNA compositions and methods of using them
US9624172B2 (en) 2014-02-17 2017-04-18 Hetero Research Foundation Polymorphs of lomitapide and its salts
RS57970B1 (sr) 2014-03-20 2019-01-31 Cymabay Therapeutics Inc Tretman intrahepatičkih holestatskih oboljenja
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
KR102374499B1 (ko) 2014-04-11 2022-03-14 사이머베이 쎄라퓨틱스, 인코퍼레이티드 Nafld 및 nash 의 치료
BR102015025502B1 (pt) * 2015-04-30 2022-06-21 Aegerion Pharmaceuticals, Inc Composição de lomitapida, tablete, produto de lomitapida, métodos para analisar uma composição de amostra de lomitapida e para determinar uma quantidade de uma impureza em uma amostra da composição
CN108348541A (zh) * 2015-08-25 2018-07-31 阿尔尼拉姆医药品有限公司 用于治疗前蛋白转化酶枯草杆菌蛋白酶kexin(pcsk9)基因相关障碍的方法和组合物
CN105481758A (zh) * 2016-01-13 2016-04-13 天津药物研究院有限公司 一种洛美他派晶型ⅰ及其制备方法和用途
MA43734A (fr) 2016-03-03 2018-11-28 Regeneron Pharma Procédés de traitement de patients atteints d'hyperlipidémie par administration d'un inhibiteur de pcsk9 en combinaison avec un inhibiteur d'angptl3
FI3448426T3 (fi) * 2016-04-28 2025-07-18 Regeneron Pharma Menetelmiä familiaalista hyperkolesterolemiaa sairastavien potilaiden hoitoon
WO2017200715A1 (en) * 2016-05-19 2017-11-23 Cymabay Therapeutics, Inc. Treatment of severe hyperlipidemia
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
WO2019101151A1 (zh) * 2017-11-23 2019-05-31 浙江海正药业股份有限公司 一种海泽麦布和HMG-CoA还原酶抑制剂的药物组合物
CN113710808A (zh) * 2018-12-20 2021-11-26 宾夕法尼亚州大学信托人 用于治疗家族性高胆固醇血症的基因疗法
BR112021013807A2 (pt) 2019-01-18 2021-11-30 Astrazeneca Ab Inibidores de pcsk9 e seus métodos de uso
US12559551B2 (en) 2019-05-24 2026-02-24 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-ANGPTL3 antibodies
WO2021097034A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Seladelpar for use in the treatment of intestinal barrier dysfunction and associated diseases
US20210145774A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Treatment of alcoholic liver disease
CA3186856A1 (en) 2020-07-29 2022-02-03 Ruth NALLEN Lomitapide for use in methods of treating hyperlipidemia and hypercholesterolemia in pediatric patients

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US5883109A (en) 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
US6066653A (en) 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
WO2005042478A2 (en) 2003-09-19 2005-05-12 Janssen Pharmaceutica, N.V. 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
KR101494067B1 (ko) 2004-03-05 2015-02-16 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 부작용을 최소화하면서 과지질혈증 및 과콜레스테롤혈증과 연관된 질환 또는 질병의 치료 방법
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
CA2740874C (en) * 2008-10-17 2018-02-27 Metabolex, Inc. Use of ppar.gamma.agonists to reduce small dense ldl particles
JOP20200043A1 (ar) * 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول

Similar Documents

Publication Publication Date Title
JP2017505285A5 (https=)
JP2017513836A5 (https=)
HRP20192299T1 (hr) Liječenje nafld i nash
HK1224186A1 (zh) 纯阖家族型高胆固醇血症的治疗
JP2017508817A5 (https=)
AR122580A2 (es) Forma de dosificación de doxilamina y piridoxina y/o sus metabolitos o sales
JP2016513717A5 (https=)
CY1119575T1 (el) Ενωσεις υποκατεστημενης βενζαλδεϋδης και μεθοδοι για τη χρηση τους στην αυξηση της οξυγονωσης του ιστου
CY1120939T1 (el) Συνδυασμος ρεγοραφενιμπης και ακετυλοσαλικυλικου οξεος για τη θεραπευτικη αντιμετωπιση του ορθοκολικου καρκινου
EP4663636A3 (en) Trifluoromethyl substituted pyrazoles as human plasma kallikrein inhibitors
JP2014221779A5 (https=)
JP2015078230A5 (https=)
JP2014218522A5 (https=)
JP2014507446A5 (https=)
UA109698C2 (xx) Похідні азаіндазолу або діазаіндазолу як медикамент
JP2014511891A5 (https=)
WO2015025228A3 (en) Compositions and therapeutic methods for accelerated plaque regression
CN109563060A (zh) Ido1抑制剂及其制备方法和应用
JP2016511753A5 (https=)
MX2017002967A (es) Composicion farmaceutica novedosa que contiene derivado de acido hidroxamico o sal del mismo.
JP2016510326A5 (https=)
MX2020010300A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
NZ602029A (en) Use of meloxicam for the long-term treatment of kidney disorders in cats
EP2987786A4 (en) AMIDOPYRIDINOL DERIVATIVE OR PHARMACEUTICAL, SALT AND PHARMACEUTICAL COMPOSITION THEREFOR AS ACTIVE SUBSTANCE
JP2015516419A5 (https=)